Towards Healthcare
Gene Therapy Clinical Trials Market Growth Forecast 2025 to 2034

Gene Therapy Clinical Trials Market 2025 Trends Report

The growing demand for gene therapy and stringent regulatory policies drive the global market. North America dominated the market due to its favorable clinical trial infrastructure and new product launches.

  • Insight Code: 6068
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

Gene Therapy Clinical Trials Market is projected to witness robust growth from 2025 to 2034, driven by rising investments, innovation, and increasing global demand.

North America is leading the gene therapy clinical trials market due to a favorable clinical trial infrastructure, the presence of key players, and expanding manufacturing capacity.

Some key players include Novartis, CRISPR Therapeutics, and Verve Therapeutics.

The first disease treated by gene therapy was SCID (Severe Combined Immunodeficiency Disorder).

The latest technologies for gene editing include SeekRNA, STITCHR, and mvGPT.

Clinicaltrials.gov, Food and Drug Administration, American Society of Gene & Cell Therapy, Government of Canada, Press Information Bureau